Attached files
| file | filename |
|---|---|
| 8-K - INTERLEUKIN GENETICS INC | v194296_8k.htm |
| EX-99.2 - INTERLEUKIN GENETICS INC | v194296_ex99-2.htm |
EXHIBIT
99.1
Interleukin
Genetics Moves Trading of Stock to OTCQB Marketplace
WALTHAM,
MA — August 16, 2010 - Interleukin Genetics, Inc. (OTCQB: ILIU) today
announced that trading of shares of the Company’s common stock will be
transferred from the NYSE Amex to the OTCQB™
Marketplace effective today, August 16, 2010. Investors in the Company can trade
the stock easily in this marketplace, where Interleukin Genetics’ symbol will
now be ILIU. The OTCQB market tier was recently introduced to better
distinguish OTC securities that are registered and fully reporting with the
Securities and Exchange Commission (SEC) or a banking or insurance regulator.
Investors can now view real time stock quotes for ILIU at http://www.otcmarkets.com.
“Trading
on the OTCQB brings a level of market maker transparency, which is good for our
shareholders. Our marketplace transfer will enable the Company to
stay focused on dedicating resources to partnering and driving continued revenue
growth of our Inherent Health brand of genetic tests,” said Lewis H. Bender,
CEO. “We just announced a significant increase in quarterly revenue and a new
major funded partnership. We will continue to pursue additional relationships
with companies involved in markets that align with our products.”
About
Interleukin Genetics, Inc.
Interleukin
Genetics, Inc. (OTCQB: ILIU) develops and markets genetic tests that empower
consumers to prevent chronic diseases and that assist pharmaceutical companies
in the development and marketing of targeted therapeutics. The Company leverages
its research, intellectual property and biomarker development experience to
facilitate the emerging personalized health market. Interleukin Genetics markets
a line of genetic tests under the Inherent Health brand including Bone Health,
Weight Management, Heart Health and Nutritional Needs. The Company is
headquartered in Waltham, MA. For more information please visit http://www.ilgenetics.com.
Certain statements contained herein
are “forward-looking” statements, including statements regarding the Company’s
ability to establish new partnerships. Because such statements include
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to, those risks
and uncertainties described in the Company’s annual report on Form 10-K
for the year ended December 31, 2009 and other filings with the Securities and
Exchange Commission. The Company disclaims any obligation or intention to update
these forward-looking statements.
# # #
Contact:
Erin
Walsh
Interleukin
Genetics
781-419-4707
ewalsh@ilgenetics.com